Core Viewpoint - The interim analysis of the KN026 clinical trial indicates that KN026 combined with chemotherapy shows clinically meaningful and statistically significant benefits in progression-free survival (PFS) and overall survival (OS) compared to placebo combined with chemotherapy, suggesting it as a potential new treatment option for HER2+GC/GEJ patients who have progressed after prior trastuzumab-based therapy [2]. Group 1: Clinical Trial Details - The KN026-001 trial, a Phase III clinical study, involves HER2+GC/GEJ patients who progressed after trastuzumab-based treatment, randomized to receive either KN026 combined with chemotherapy or placebo combined with chemotherapy [1]. - Baseline characteristics of both patient groups were balanced, with a median age of approximately 64 years for the KN026 group and 61 years for the control group, and over 80% of patients in both groups having an ECOG PS score of 1 [1]. Group 2: Mechanism and Future Trials - KN026 is designed to be a next-generation HER2-targeted therapy, capable of binding to two different clinically validated HER2 epitopes while retaining the wild-type Fc region, allowing for dual blockade of HER2-related signaling pathways and enhanced tumor-killing effects [2]. - Multiple Phase III clinical trials are currently underway in China, including studies of KN026 combined with docetaxel for first-line treatment of HER2+ breast cancer and for second-line treatment of HER2+GC/GEJ [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 1 結論：期中分析顯示，與安慰劑聯合化療相比，KN026聯合化療在PFS和OS方 面均取得具有臨床意義和具有統計學顯著性的獲益，且具有良好可控的安全性特 徵。該等結果表明，對於既往接受過曲妥珠單抗為基礎的治療後出現疾病進展的 HER2+ GC/GEJ患者，KN026聯合化療可作為一種有潛力的新治療選擇。 關於KN026 KN026旨在成為全球性新一代HER2靶向療法。憑藉其創新的結構，可同時結合 至兩種不同的經臨床驗證的HER2表位（表位II及IV），並保留野生型Fc區。這使 得KN026能夠(i)雙重阻斷HER2相關信號通路，(ii)增強與HER2受體的結合，(iii) 減少細胞表面的HER2蛋白，及(iv)通過完整的抗體依賴性細胞介導的細胞毒性增 強對腫瘤的殺傷效果。該等結合機制使KN026表現出卓越的腫瘤抑制作用。 康寧傑瑞生物製藥 （於開曼群島註冊成立的有限公 ...

Market Overview - The Hang Seng Index fell by 1.61%, down 415 points, closing at 25,472 points, while the Hang Seng Tech Index dropped by 2.81%. The early trading volume in the Hong Kong market was HKD 153.2 billion [1] Energy Sector - Gas stocks rose, with Zhongyu Energy (03633) increasing by over 10%. This surge is attributed to the early initiation of winter heating in Gansu and other regions due to continuous temperature drops, leading to increased natural gas demand [1] Biotechnology Sector - Newly listed stock Xuan Zhu Bio-B (02575) surged over 13%, reaching a new high, and is up more than 190% from its IPO price. Yimai Sunshine (02522) rose over 4% following the global launch of its medical imaging model product AIR. The performance of medical stocks varied, with Yaojie Ankang-B (02617.HK) up over 21%, Baize Medical (02609) up over 5%, while Kangfang Biotech (09926) fell by 2%. Kangning Jereh Pharma-B (09966) increased by over 13% after announcing a share buyback plan, with market attention on significant data from the ESMO conference [2] Precious Metals Sector - Laopu Gold (06181) rose over 4%, benefiting from increased channel expansion and upgrades, with institutions indicating that rising gold prices favor its high-end brand positioning [3] Hospitality Sector - Wanda Hotel Development (00169) increased by over 10% after completing a sale and announcing a special dividend of HKD 0.462 per share to be paid next month [4] Digital Assets Sector - Delin Holdings (01709) rose over 3% after entering a strategic cooperation agreement with Antalpha to promote business in the digital asset sector [5] Telecommunications Sector - Changfei Optical Fiber and Cable (06869) fell over 6%, having dropped 40% from its September peak due to declining fiber optic prices and shareholder sell-offs. Cryptocurrency-related stocks collectively declined, with Bitcoin experiencing significant volatility and a recent incident in the US stablecoin market. Mi Strategy (02440) fell by 4.36%, and OSL Group (00863) dropped by 3.99% [6] Semiconductor Sector - Chip stocks continued to decline, with SMIC (00981) down over 5% and Huahong (01347) down over 3%, as US export controls accelerate domestic semiconductor replacements [6]

Core Insights - The biotechnology sector in the Hong Kong stock market has shown strong performance, with several stocks experiencing significant gains today, particularly药捷安康-B which surged over 30% [1] Stock Performance Summary - 药捷安康-B: Increased by 31.25%, latest price at 218.000, total market value of 86.524 billion, year-to-date increase of 1557.79% [2] - 康宁杰瑞制药-B: Increased by 7.15%, latest price at 14.680, total market value of 14.245 billion, year-to-date increase of 319.43% [2] - 帝王国际投资: Increased by 5.50%, latest price at 0.115, total market value of 0.0213 billion, year-to-date increase of 155.56% [2] - 映恩生物-B: Increased by 5.00%, latest price at 336.000, total market value of 29.58 billion, year-to-date increase of 255.18% [2] - 基石药业-B: Increased by 4.66%, latest price at 7.190, total market value of 10.612 billion, year-to-date increase of 212.61% [2] - 三叶草生物-B: Increased by 4.39%, latest price at 2.140, total market value of 2.776 billion, year-to-date increase of 787.97% [2] - 百奥塞图-B: Increased by 3.86%, latest price at 24.220, total market value of 9.673 billion, year-to-date increase of 184.94% [2] - 来凯医药-B: Increased by 3.71%, latest price at 14.540, total market value of 6.49217 billion, year-to-date increase of 55.18% [2] - 君实生物: Increased by 3.29%, latest price at 27.600, total market value of 28.337 billion, year-to-date increase of 138.34% [2] - MIRXES-B: Increased by 3.26%, latest price at 72.900, total market value of 20.145 billion, year-to-date increase of 212.88% [2]

Group 1 - Corning Pharmaceutical-B (09966.HK) experienced a rise of over 7%, with a current increase of 6.79%, trading at 14.63 HKD [1] - The trading volume reached 37.113 million HKD [1]

Core Viewpoint - 康宁杰瑞制药-B (09966) shares increased by over 7%, currently trading at 14.63 HKD with a transaction volume of 37.113 million HKD, following the announcement of a share buyback program [1] Group 1: Share Buyback Announcement - 康宁杰瑞制药 announced a share buyback of 400,000 shares for a total cost of 5.483 million HKD [1] - The company has a maximum buyback limit of 20 million HKD, authorized by the board based on a general mandate approved by shareholders at the annual general meeting on June 12, 2025 [1] Group 2: Upcoming Events - The European Society for Medical Oncology (ESMO) will take place from October 17 to 21 in Berlin, Germany, where the latest research abstracts will be presented [1] - A total of 23 studies from China, including key research on 康宁杰瑞's KN026, have been selected for presentation at the ESMO [1]

Group 1 - Corning Pharmaceutical-B (09966) saw a stock increase of over 7%, currently trading at 14.63 HKD with a transaction volume of 37.113 million HKD [1] - The company announced a share buyback of 400,000 shares for a total cost of 5.483 million HKD, as part of a broader authorization to repurchase shares up to a maximum of 20 million HKD [1] - The European Society for Medical Oncology (ESMO) conference will take place from October 17 to 21 in Berlin, with 23 research studies from China, including key studies like Corning's KN026, being presented [1]

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on October 16, 2025, with Xiaomi Group-W leading in terms of buyback amount and quantity [1] Group 1: Buyback Details - Xiaomi Group-W (01810) repurchased 4 million shares for a total of 192 million [1] - Mengniu Dairy (02319) repurchased 1 million shares for 14.44 million [2] - Yun Gongchang (N23027) repurchased 2.01 million shares for 8.19 million [2] Group 2: Cumulative Buyback Data - Xiaomi Group-W has a cumulative buyback of 16.59 million shares, representing 0.060% of total share capital [2] - Mengniu Dairy has a cumulative buyback of 17.32 million shares, representing 0.443% of total share capital [2] - Yun Gongchang has a cumulative buyback of 20.62 million shares, representing 4.483% of total share capital [2] Group 3: Other Notable Buybacks - Lianyi Rong Technology-W (09959) repurchased 2.39 million shares for 7.48 million, with a cumulative total of 60.47 million shares, representing 2.830% of total share capital [2] - Kangning Jiere Pharmaceutical-B (09966) repurchased 400,000 shares for 5.48 million, with a cumulative total of 801,000 shares, representing 0.083% of total share capital [2] - Guisheng Tongqiao-B (02190) repurchased 50,000 shares for 1.24 million, with a cumulative total of 330,350 shares, representing 1.009% of total share capital [2]

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966.HK) repurchased 400,000 shares on October 16, 2025, at a total cost of HKD 5.483 million, indicating a strategic move to enhance shareholder value [1][2]. Group 1: Share Buyback Details - The company repurchased shares at prices ranging from HKD 13.520 to HKD 13.820 per share [1]. - The closing price on the day of the buyback was HKD 13.700, reflecting a 2.54% increase in share price [1]. - The total trading volume for the day was HKD 35.6313 million [1]. Group 2: Year-to-Date Buyback Summary - Year-to-date, the company has conducted three buyback transactions, totaling 801,000 shares repurchased [2]. - The cumulative amount spent on buybacks this year is HKD 10.9358 million [2]. - Detailed buyback transactions include: - October 16: 400,000 shares at a maximum price of HKD 13.820 and a minimum price of HKD 13.520, costing HKD 5.483 million [2]. - October 14: 293,000 shares at a maximum price of HKD 13.830 and a minimum price of HKD 13.030, costing HKD 3.9669 million [2]. - October 13: 108,000 shares at a maximum price of HKD 13.800 and a minimum price of HKD 13.690, costing HKD 1.4860 million [2].

智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2025年10月16日，该公司斥资548.3万港元回购 40万股。 ...